Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 6, 2010, Pages 939-944

  Yorozuya, Kyoko ^a   Takeuchi, Toru ^b   Yoshida, Miwa ^a   Mouri, Yukako ^a   Kousaka, Junko ^a   Fujii, Kimihito ^a   Nakano, Shogo ^a   Fukutomi, Takashi ^a   Hara, Kazuo ^a   Ichihara, Shu ^c   Lin, Yingsong ^a   Kikuchi, Shogo ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Surgery   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Adjuvant therapy; Breast cancer; ER positive; Japanese women; Node negative; Oncotype DX

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ASIAN; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; CHEMISTRY; EVALUATION; FEMALE; HUMAN; JAPAN; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RETROSPECTIVE STUDY; RISK; STATISTICS; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 77951631346     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-009-0736-8     Document Type: Article

References (6)

1. Balan V, Nangia-Makker P, Schwartz AG, Jung YS, Trait L, Hogan V, Raz T, Wang Y, Yang ZQ, Wu GS, Guo Y, Li H, Abrams J, Couch FJ, Lingle WL, Lloyd RV, Ethier SP, Tainsky MA, Raz A (2008) Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res 68:10045-10050
2. Kamo K, Katanoda K, Matsuda T, Marugame T, Ajiki W, Sobue T (2008) Lifetime and age-conditional probabilities of developing or dying of cancer in Japan. Jpn J Clin Oncol 38:571-576
3. Matsuda T, Marugame T, Katanoda K, Ajiki W, Sobue T, the Japan Cancer Surveillance Research Group (2008) Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. Jpn J Clin Oncol 38:641-648
4. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
5. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T (1999) Monitoring of interobserver agreement in nuclear atypia scoring of node-negative breast carcinomas judged at individual collaborating hospitals in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Clin Oncol 29:413-420
6. Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B (2008) Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. Cancer 112:731-736